$ABT

Stratton John G purchased $174K of ABT

Stratton John G purchased 2,000 shares of ABBOTT LABORATORIES (ABT) at $86.82 ($0.17M total) on 2026-05-07.

Original reporting
SEC EDGAR · Stratton John G
Published Jun 18, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ABT
Bullish
medium confidence
Mentioned
$ABT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTBullishLow
01

Why it matters

A director’s open-market purchase adds a small positive sentiment datapoint but does not introduce new operational, financial, or regulatory information.

02

Market read

Traders may note insider buying, but the lack of fundamental catalysts suggests limited trading edge.

03

What to watch

No 10b5-1 plan and the filing date lags the trade date; the market may already have priced any sentiment effect.

Relevance 5/10Novelty 5/10Timing: new Form 4 filed 2026-06-18 (covers 2026-05-07 purchase)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Abbott Laboratories.

Company-level read

Ticker impact

$ABTBullishMedium confidence
Context

Abbott Laboratories director Stratton John G filed a Form 4 open-market purchase of 2,000 shares at $86.82 on 2026-05-07.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

Form 4 provides a fresh datapoint (insider buying), yet the transaction size and lack of accompanying corporate news reduce tradable signal strength.

Market effects

Minimal; single-insider transaction without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (e.g., diversification or compensation-related) and may not reflect a strong forward view.

Key entities

  • Abbott Laboratories

    Issuer of the Form 4; insider purchase disclosed.

  • Stratton John G

    Director who purchased 2,000 ABT shares at $86.82.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABTMedAI 8/10

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

$ABTHighAI 8/10

Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula

Abbott Laboratories will pay $385M to resolve allegations of tainted infant formula. The settlement includes $348.7M to the federal government and $35.5M to state Medicaid programs. California's share is over $15M. The allegations span 2018-2022, involving production conditions that risked microorganism contamination. Abbott recalled several formula brands in 2022, leading to a nationwide shortage.

$ABTLowAI 8/10

Sunday Edition: Sodium

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

$ABTLow

State settles infant formula contamination lawsuit, more Health Headlines

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.